In this study, two FRGs (ABCC1 and GLS2) were used in the prognostic risk model, which was an independent prognostic biomarker related to EB subtype, clinical stage and survival status in NPC. This evidence concerns the gene GLS2 and nasopharyngeal carcinoma.